Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | Myeloma: immunomodulatory therapy and CHIP

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the rationale behind the use of immunomodulatory therapy in the treatment of multiple myeloma and the importance of clonal hematopoiesis of undetermined potential (CHIP) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.